Evidence map›Paper›PMID 40645301›Full record

ReviewAlcohol (Fayetteville, N.Y.)2025

Alcohol, aging, and the gut microbiome: Intersections of immunity, barrier dysfunction, and disease.

Esther Melamed, Wiramon Rungratanawanich, Suthat Liangpunsakul, Katherine A Maki, Rebecca L McCullough, Cristina Llorente

Abstract readReview
In one paragraph

Review in Alcohol (Fayetteville, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Esther MelamedDepartment of Neurology, The University of Texas at Austin, Dell Medical School, Austin, TX, USA.
Wiramon RungratanawanichSection of Molecular Pharmacology and Toxicology, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA.
Suthat LiangpunsakulDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA; Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA.
Katherine A MakiBiobehavioral and Integrated MetagenOMics (BIOM) Unit, Translational Biobehavioral and Health Disparities Branch, National Institutes of Health Clinical Center, Bethesda, MD, USA.
Rebecca L McCulloughSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Electronic address: rebecca.mccullough@ucdenver.edu.
Cristina LlorenteDivision of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, CA, USA. Electronic address: allorenteizquierdo@health.ucsd.edu.

Funding

The Southernearch Center for ALPD and CirrhosisP50AA011999 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HIDEKAZU TSUKAMOTO · 1999 to 2026
$45.8M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LARS ECKMANN, Bernd G. Schnabl · 2019 to 2026
$10.8M
Goblet cells and intestinal immune response in alcohol-associated liver diseaseR01AA029106 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ana Cristina Llorente Izquierdo · 2022 to 2026
$2.3M
Neuroinflammatory GeroMiRs and Alcohol: Defining Mechanisms of ADRDR01AA030741 · NIAAA · UNIVERSITY OF COLORADO DENVER · PI Rebecca LeAnne Smathers McCullough · 2024 to 2026
$1.4M
The role of intestinal gp130 in alcohol-associated liver diseaseR21AA030654 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LLORENTE IZQUIERDO, ANA CRISTINA · 2023 to 2023
$415k
Intramural NIH HHS Z99 CL999999NIAAA NIH HHS P50 AA011999NIAAA NIH HHS R01 AA029106NIAAA NIH HHS R01 AA030741NIAAA NIH HHS R21 AA030654NIDDK NIH HHS P30 DK120515
6 · The paper itself

Abstract

Alcohol consumption exerts complex, dose- and context-dependent effects on human health, particularly by influencing the gut microbiome, intestinal barrier integrity, immune regulation, and aging processes. Genetic variation and advancing age are two major, and often interacting, factors that modify the risk of alcohol-related diseases. Among genetic factors, the prevalent aldehyde dehydrogenase 2 polymorphism (ALDH2∗2) compromises acetaldehyde clearance, driving toxic metabolite accumulation, oxidative stress, and increased intestinal permeability that disrupts gut microbial communities, even at low levels of alcohol consumption. Heavy and chronic alcohol use further disrupts gut microbial communities, erodes mucosal integrity, and drives systemic inflammation, contributing to alcohol-associated liver disease (ALD), neuroinflammation, and multi-organ injury. Aging independently worsens these effects by promoting chronic low-grade inflammation and impaired immune responses, heightening susceptibility to alcohol-induced pathology. In specific contexts, such as certain autoimmune diseases, low to moderate alcohol intake may exert immunomodulatory effects and influence the gut microbiome, potentially contributing to reduced inflammation and alterations in microbial composition. This review synthesizes current mechanistic insights into how alcohol, host genetics, the gut microbiome, immune regulatory pathways, and aging intersect to influence disease risk. As global populations age and the burden of alcohol-related health issues rises, there is an urgent need for integrated, systems-level approaches. Future research should prioritize precision-based, gut-targeted strategies aimed at restoring microbial balance, maintaining intestinal barrier integrity, and mitigating alcohol-related harm across the lifespan.

Indexed as

AgingAlcohol DrinkingEthanolGastrointestinal MicrobiomeAnimalsHumansInflammationIntestinal MucosaEthanolAlcoholGut-brain axisGut-liver axisMicrobiomeNeuroinflammation

Identifiers

PMID40645301
PMCPMC12911496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.